1. Pink Sheet
  2. >>Biosimilars & Generics
  3. >>Generics

Complex Generics: US FDA, Sponsors View Roadblocks Very Differently

 
• By Derrick Gingery

As GDUFA III negotiations continue, FDA doesn’t seem ready to make additional changes to approval process, but industry argues guidance practices and communications need fixing and that consumers are missing out on potential savings because of it.

The US FDA approval process for complex generic drugs continues to vex sponsors, who want a more predictable timeline. • Source: Shutterstock

ANDA sponsors feel some more tweaking of the assessment process is necessary to speed approval of complex generics, but the US Food and Drug Administration appears more willing to wait for the current process to bear fruit.

In what may be a rare case of indirectly open generic drug user fee reauthorization negotiating, generic sponsors suggested several changes during a 9 February webinar hosted by The Hill and sponsored by the Association for Accessible Medicines. Teva Pharmaceutical Industries Ltd

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Biosimilars & Generics